A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia

• Status: Completed
• Trial end date: 2013-10-17
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety and tolerability of multiple doses of PF 02545920 administered orally to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/- other adjunctive medication.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Psychiatrically stable subjects with schizophrenia.

• Evidence of stable schizophrenia symptomatology greater than or equal to 3 months.

• Subjects must be on a stable medication treatment regimen greater than or equal to 2 months, including concomitant psychotropic medications.

Exclusion Criteria:

• History of seizures or of a condition with risk of seizures.

• Subjects who have had electroconvulsive therapy within the 6 months prior to randomization.

• Pregnant or nursing females, and females of child bearing potential.